|Dr. Peter A. Thompson M.D.||Co-Founder & Chairman of Directors||N/A||N/A||1959|
|Dr. Valerie Odegard Ph.D.||Pres & Chief Scientific Officer||415.09k||N/A||1977|
|Dr. Naomi Hunder M.D.||Chief Medical Officer||426.54k||N/A||1969|
|Dr. Laura K. Shawver||CEO & Director||N/A||N/A||1958|
|Mr. Jonathan Piazza||Chief Financial Officer||N/A||N/A||1975|
|Mr. Jeffrey C. Pepe J.D., Ph.D.||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Katie Carrigan||VP of HR||N/A||N/A||N/A|
|Mr. Russ Hawkinson||Sr. VP of Fin.||N/A||N/A||N/A|
|Mr. Scott Moorefield Ph.D.||Sr. VP of Bus. Devel.||N/A||N/A||N/A|
|Mr. Sateesh Natarajan||Sr. VP of CMC Devel.||N/A||N/A||N/A|
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Silverback Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.